Short Interest in NeuroSense Therapeutics Ltd. (NASDAQ:NRSNW) Drops By 13.5%

NeuroSense Therapeutics Ltd. (NASDAQ:NRSNW) was the target of a large decrease in short interest in February. As of February 13th, there was short interest totaling 6,511 shares, a decrease of 13.5% from the January 29th total of 7,529 shares. Based on an average daily trading volume, of 1,762 shares, the days-to-cover ratio is presently 3.7 days. Based on an average daily trading volume, of 1,762 shares, the days-to-cover ratio is presently 3.7 days.

NeuroSense Therapeutics Stock Up 9.5%

NeuroSense Therapeutics stock traded up $0.02 during midday trading on Thursday, hitting $0.21. 200 shares of the company’s stock were exchanged, compared to its average volume of 1,578. NeuroSense Therapeutics has a 12 month low of $0.16 and a 12 month high of $1.00. The firm has a 50-day moving average of $0.27 and a two-hundred day moving average of $0.36.

About NeuroSense Therapeutics

NeuroSense Therapeutics Ltd., a clinical-stage biotechnology company, focuses on discovering and developing treatments for patients suffering from debilitating neurodegenerative diseases in the United States and internationally. The company's lead product is PrimeC, an extended-release oral formulation of a fixed-dose combination of ciprofloxacin and celecoxib, currently under Phase 2b/3 clinical trials for the treatment of amyotrophic lateral sclerosis, and completed Phase 2 clinical trials for the treatment of Alzheimer's, as well as under preclinical studies for the treatment of Parkinson's disease.